TCTR20211120002已完成4 期
Immunogenicity of the third COVID-19 vaccine booster dose in adults with completed 2 doses as recommended by the ministry of public health
ational Research Council of Thailand (NRCT)0 个研究点目标入组 300 人开始时间: 2021年11月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
After booster, a significant increase in binding antibodies and neutralizing activities toward delta and omicron variants was observed. Neutralization to omicron BA.1 and BA.2 were comparable, showing the highest titers after boosted mRNA-1273 followed by BNT162b2 and AZD1222. In addition, individuals boosted with messenger RNA (mRNA) vaccines develop a T-cell response to spike protein, whereas those boosted with AZD1222 did not. Reactogenicity was mild to moderate without serious adverse events.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Healthy Thai individuals above 18 years of age
- •2. Not previously infected with COVID-19
- •3. Provide informed consent
排除标准
- •1. Previously infected with COVID-19
- •2. Immunocompromised individuals
研究者
相似试验
已完成
不适用
Effect of a Third COVID-19 Booster Among Health Care WorkersCOVID-19 VaccinesNCT05373459Hong Kong Sanatorium & Hospital3,167
已完成
3 期
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish InfantsPolioHepatitis BDiphtheriaPertussisNCT00619502Sanofi Pasteur, a Sanofi Company254
已完成
不适用
Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in JapaAdverse events of vaccinationJPRN-UMIN000010672Saga University100
招募中
不适用
Immune response to the 3rd dose booster with mRNA-1273 COVID-19 vaccine in individuals who had received 2 doses of CoronaVac or ChAdOx-1 COVID-19 vaccineTCTR20211115003Thammasat University Hospital100
已完成
2 期
COVID-19 Protection After Transplant Pilot StudyKidney Transplant RecipientsNCT04969263National Institute of Allergy and Infectious Diseases (NIAID)81